Blog

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and placebo. This manufacturing run will provide the Company with clinical drug supply for later stage clinical studies.

“We are delighted to be working with a leading global contract manufacturing organization,” said James Rolke, Chief Executive Officer of Revelation. “The manufacture of additional drug supply and placebo will fulfill a critical step in advancing Revelation’s pipeline and accelerating timelines for upcoming clinical programs.”

The manufacture of drug and Placebo enables the company to conduct randomized double blinded, placebo-controlled clinical studies, and is an integral part of the broader strategy to move Gemini toward approval.

Revelation met with FDA in December 2025 and is currently awaiting the official meeting minutes. The primary purpose of this meeting was to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).

About Gemini

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD^®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEMINI-AKI program). Gemini is also being developed as a treatment for chronic kidney disease (GEMINI-CKD program), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI) and as a treatment to prevent post-surgical infection (GEMINI-PSI program). The potential of Gemini has been demonstrated in multiple preclinical models of AKI, CKD and infection, as well as in two phase 1 clinical studies. See additional detail here.

About AKI

Acute Kidney Injury or AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease and death.

AKI is a major cause of morbidity and mortality, affecting more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units. Renal replacement therapy (dialysis) is still the only therapeutic option in the treatment of the consequences of severe AKI and is required in approximately 20% of all critically ill patients. Despite the fact that these patients show high mortality rates, up to 40% of patients who survive such an episode develop chronic kidney disease or end-stage renal disease. As such, new therapies to treat AKI are currently needed.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

LOS ANGELES, CA / ACCESS Newswire / January 7, 2026 / An affiliate of Pacific Avenue Capital Partners (“Pacific Avenue”) is pleased to announce the sale of Emerald Textiles (“Emerald”) to Purestar Linen Group (“PureStar”), a leading North American provider of outsourced laundry services to the hospitality industry.

Emerald is the largest acute care linen service provider in the Western U.S., operating twelve commercial linen processing facilities and three service depots. Emerald provides a full suite of products encompassing traditional linens and add-ons such as mops, mats, and scrubs.

Under Pacific Avenue’s ownership since 2017, Emerald was transformed into the leading healthcare service provider in the Western U.S. Pacific Avenue grew the business through four add-on acquisitions, a greenfield expansion, and several large customer wins, while also making Emerald a better business by optimizing its processing footprint, investing in its equipment and facilities, and implementing a process and culture of continuous improvement.

“Emerald exemplifies the Pacific Avenue investment strategy of buying fundamentally good businesses and unlocking value through operational improvement, capital investment, and accelerated growth,” said Chris Sznewajs, Founder and Managing Partner of Pacific Avenue. “We take pride in Emerald’s extraordinary transformation under our ownership. The company capitalized on Pacific Avenue’s experience and ability to build industry-leading companies. We congratulate and thank Andy Kratky, Emerald’s Chief Executive Officer, and the senior management team for their strategic vision, tremendous execution, and passion.”

Andy Kratky added, “Pacific Avenue recognized the potential to create value by investing in our company. Working with Pacific Avenue, we invested significantly in our operations and people, becoming a far better company. We are grateful to Pacific Avenue for providing our team with expertise, capital, and the resources needed to acquire and integrate four acquisitions and greenfield a state-of-the-art facility. We are confident in our growth trajectory and will continue to provide our customers with high levels of quality and customer service.“

The transaction closed on December 30, 2025. Financial terms of the transaction were not disclosed.

BakerHostetler served as legal counsel, Piper Sandler & Co. served as lead financial advisor and Lincoln International, Inc. also served as financial advisor to Pacific Avenue and Emerald with respect to the transaction.

About Pacific Avenue Capital Partners
Pacific Avenue Capital Partners is a global private equity firm, headquartered in Los Angeles with offices in Paris, France. The firm is focused on corporate divestitures and other complex situations in the middle market. Pacific Avenue has extensive M&A and operations experience, allowing the firm to navigate complex transactions and unlock value through operational improvement, capital investment, and accelerated growth. Pacific Avenue takes a collaborative approach in partnering with strong management teams to drive lasting and strategic change while assisting businesses in reaching their full potential. Pacific Avenue has approximately $3.8 billion of Assets Under Management (AUM) as of September 30, 2025. The members of the Pacific Avenue team have closed over 120 transactions, including over 50 corporate divestitures, across a multitude of industries throughout their combined careers. For more information, please visit www.pacificavenuecapital.com.

About Emerald Textiles
Emerald is the largest acute care linen service provider in the Western U.S., operating twelve commercial linen processing facilities and three service depots. Emerald provides a full suite of products encompassing traditional linens and add-ons (e.g., mops, mats, scrubs, and isolation gowns) and is committed to providing the best value-proposition to customers through the highest quality and service in its geographies. To learn more, please visit www.emeraldus.com.

Contact Information

Chris Baddon
Principal
cbaddon@pacificavenuecapital.com

SOURCE: Pacific Avenue Capital Partners

View the original press release on ACCESS Newswire

Scalable Production Grade AI Orchestration Proven to be 55x More Capital Efficient than Utility-Scale Batteries

OTTAWA, ON / ACCESS Newswire / January 7, 2026 / BluWave-ai announced today the production-scale deployment of the EV Everywhere™ platform across Canadian grids and diverse EV models building on its previous announcement of the patent pending Pan-Canadian EV Everywhere Infrastructure Cube.

The launch comes at a pivotal moment for the Canadian energy sector. Electric Mobility Canada recently announced that Canada has surpassed the milestone of 1 million electric vehicles registered nationwide, on track to meet the federal mandate of 4.6 million ZEVs on the road by 2030. Ontario alone is facing a projected fleet of 11.5 million EVs by 2050, requiring up to $92 billions in grid upgrades. The EV Everywhere™ platform offers a proven pathway to manage growing electrification demands while avoiding hundreds of billions in capital-intensive “poles and wires” upgrades across Canada.

“When just 33 percent of Canada’s current 1 million EVs get on the platform, it offers grids across the country approximately 2.5 GW of power capacity and 20 GWh of storage capacity-which is enough to power the entire British Columbia grid for two hours alone,” said Devashish Paul, CEO and founder of BluWave-ai. “This turns a potential grid liability into a massive, distributed battery that can be dispatched whenever the system is under stress.”

Expanding Ecosystem with Smartcar
Central to this nationwide rollout is BluWave-ai’s continued collaboration with Smartcar, building on their 2023 agreement to integrate vehicle APIs for direct-to-car communication. Through this partnership, BluWave-ai and Smartcar conducted extensive testing to validate managed charging across a wide spectrum of automotive brands, including Tesla, Kia, Hyundai, Ford, GM, BMW, Jaguar, Mini, and Porsche. This validation ensures that the EV Everywhere™ platform can reliably orchestrate diverse EV fleets across various provincial grids, regardless of the charging hardware used.

“We take on the last mile connectivity to a variety of EV models and work with application operators like BluWave-ai to ensure that by connecting to our cloud, the interface to EV OEMs is seamless and believe that this partnership will accelerate the integration of EVs into the Canadian smart grid, enabling more efficient, and sustainable energy management, and most importantly freeing up BluWave-ai to run the grid optimization using the EVs that we connect them to,” said Sahas Katta, CEO of Smartcar.

Optimizing the Grid with EVs and Storage
The program executed 151 distinct test scenarios across summer and winter seasons, validating a “dual-resource” strategy that utilizes both EVs and Battery Energy Storage Systems (BESS).

“Based on our extensive testing over the past two years in grids across Canada, utilities should prioritize EV curtailment as the primary non-wire alternative resource due to its superior capital efficiency relative to Battery Storage,” said Thomas Triplet, VP of Technology at BluWave-ai. “BESS assets should be deployed secondarily for ‘firming’ capacity and fast-frequency response (sub-minute) where EV latency (90 seconds) is insufficient. EV capex is paid for by consumers, whereas front-of-the-meter (FOTM) batteries are either paid for by utilities or capitalized by IPPs with utility commits to long term contracts, so EVs are very attractive from a capital angle. Regardless, by combining EV Everywhere with our Energy Storage Autopilot™, our platform can aggregate the entire pool of EVs and BESS assets as a large energy storage base readily available for utilities and system operators. Our software system demonstrated the capacity to reduce peak EV charging loads by up to 35 percent and on average by 21.7 percent.”

Availability of the Energy Storage Autopilot for FOTM energy storage facilities follows deployment with Area X.O, a multi-sector research and development complex founded by Invest Ottawa, to optimize the performance of grid-scale batteries using BluWave-ai EV Everywhere complemented by BluWave-ai Energy Storage Autopilot to manage grid congestion.

Key Performance Milestones & Findings:

• Massive Capital Efficiency: Aggregating EVs was found to be ~55 times more capital-efficient than deploying equivalent utility-scale battery storage.

• Infrastructure Deferral: The platform has the potential to deliver an infrastructure deferral value of $2.3M to $7.9M per 1,000 EVs, depending on local grid conditions.

• Mitigating the ‘Timer Peak’: The system achieved 100% target adherence, reducing peak demand by up to 32% by managing the surge caused by EVs scheduling charging at the start of low overnight rate periods.

• Consumer Acceptance: By design, satisfying the EV drivers’ target departure state of charge at their selected time is primary. Opt-out rates averaged only 4%, confirming high consumer acceptance.

A Call for Regulatory Reform: To accelerate these benefits, BluWave-ai recommends that electricity system operators and provincial regulators (such as the OEB, Régie de l’énergie and BCUC where the largest EV penetration in Canada is) lower market participation thresholds to 100 kW aligning with the North American FERC 2222 standard, allow utilities to capitalize SaaS expenses for NWAs, and utilize direct EV telemetry for Measurement & Verification (M&V).

Patented Innovation at Scale: The EV Everywhere™ platform is supported by a robust suite of intellectual property that has grown to 51 patents filed internationally, with 13 patents already granted by the USPTO.

Proven Readiness for International Deployment: While currently operationalizing across Canada, the EV Everywhere™ platform is engineered for global scale-out. This is evidenced by BluWave-ai’s strategic collaboration with the Dubai Taxi Company (DTC), where the platform was deployed to provide direct connectivity to vehicles within DTC’s fleet. By leveraging AI to optimize the energy consumption and charging cycles of one of the world’s most prominent taxi fleets, BluWave-ai has demonstrated the platform’s ability to handle high-utilization commercial assets and diverse international grid requirements. This international experience ensures that EV Everywhere is ready to support utilities in any market transitioning to mass-market electric mobility.

Covering another key aspect of electrification challenging the electrical system, BluWave-ai recently announced the availability of the Data Center Autopilot™. In concert with EV Everywhere and the Energy Storage Autopilot, it provides application owners, colocation, and hyperscale data center operators a fast-to-deploy solution to manage their immense and volatile power demands in concert with the dynamics of the local grid load.

“The strain that hyperscale AI is putting on the grid is a major concern for all colocation providers, especially as we commit to meeting aggressive sustainability goals. BluWave-ai’s approach is unique because it goes beyond facility-level controls to address the power demands at the rack and application level,” said Mike Lalonde, Co-founder at Purecolo.” Integrating Data Center Autopilot allows us to provide our customers with a truly granular demand response capability, ensuring we can optimize workloads to align with the grid’s real-time cost and carbon intensity. This partnership is a key step for Purecolo to manage volatility, offer superior quality of service, and deliver on our promise of a more efficient, net-zero-ready data center.”

For EV Drivers wanting to get on the platform and earn rewards go to: ev-everywhere.ca

• Charge when your electricity rates are lowest

• Power your drive with cleaner energy

• Learn about your energy use with personalized insights

• Support the connected grid of the future

• Drive more sustainably to earn rewards and give back

For utilities and system operators seeking to manage EVs relative to load and storage, go to: https://www.bluwave-ai.com/ev-everywhere

Contact:

info@bluwave-ai.com

SOURCE: BluWave-ai

View the original press release on ACCESS Newswire

VVater will convert 40K gallons of contaminated water per day at U.S. facility

AUSTIN, TEXAS / ACCESS Newswire / January 7, 2026 / VVater, America’s Next Water Company, announced today that it has been awarded a multimillion-dollar contract by a Fortune 50 global Food & Beverage company to deliver an advanced water treatment solution at one of its major U.S. manufacturing facilities in Texas. The engagement spans ten years and reflects VVater’s expanding role as the preferred partner for enterprises seeking resilient, on-site water infrastructure.

Under the agreement, VVater will handle 100% of the facility’s discharge water, and transform 40,000 gallons of previously contaminated industrial water per day into safe, potable drinking water. This will reduce freshwater dependency while strengthening operational reliability in a region facing increasing water stress, using VVater’s award-winning Farady Reactors.

“For large industrial operators, water is no longer a utility; it’s a strategic input,” said Kevin Gast, Chairman and CEO of VVater. “Companies that run continuously and at scale need certainty, resilience, and control. That’s where VVater comes in, and in this particular case, our customer did not have years to wait for permits, construction, and retrofits. They need solutions that can be designed, deployed, and operationalized on real-world timelines.”

The customer selected VVater not only for its technical capabilities, but also for its ability to design, build, and commission a fully operational water system in a matter of weeks, rather than months or years. The rapid deployment timeline reflects VVater’s vertically integrated delivery model and modular infrastructure platform, allowing enterprises to resolve water constraints without disrupting ongoing operations. This execution velocity is increasingly critical for manufacturers facing production schedules, regulatory deadlines, and regional water uncertainty.

Industrial manufacturers across the United States are facing rising water costs, stricter discharge regulations, and heightened scrutiny from regulators, investors, and consumers. VVater’s solution enables facilities to close the loop on water use, converting impaired water into a dependable, on-site drinking water supply while reducing exposure to supply disruptions and compliance risk. By treating water at the point of use, VVater helps industrial operators lower long-term operating costs, minimize infrastructure dependencies, and insulate production from regional water volatility.

This engagement reflects a broader trend across U.S. manufacturing, where Fortune-scale operators are transitioning away from centralized, legacy water systems toward decentralized, high-performance solutions that deliver measurable outcomes.

VVater continues to be selected across industries for its ability to:

• Deliver potable-grade water from impaired sources

• Deploy quickly without disrupting operations

• Operate reliably over extended time horizons

• Align economic performance with sustainability goals

As water security becomes inseparable from business continuity, VVater is increasingly positioned as America’s Next Water Company, providing the infrastructure modern industry requires to operate, expand, and compete.

About VVater

VVater is America’s Next Water Company, delivering the future of purification through its award-winning Farady Reactor (Time Best Invention Award 2025, CES Best of Innovation 2025, World Future Award 2025, Inc Magazine Best in Business Award 2025). The first company in history to win all 4 in 1 year achieving a Triple Crown), proprietary ALTEP (Advanced Low Tension Electroporation Process), Advanced Dissolved Air Flotation, and Micro & Nano Bubble technologies. Unlike outdated chemical, filtration, and membrane systems, VVater’s electric-field breakthroughs eliminate PFAS, microplastics, microorganisms, and other contaminants with record retention times, without producing toxic byproducts or requiring costly consumables. With over 4.3B gallons treated and validation from global leaders, VVater is scaling into municipal drinking water and wastewater, DPR/IPR, onsite reuse for data centers, commercial buildings, and resorts, residential purification, and consumer health water, delivering a 60% smaller footprint, 40% CapEx savings, 80% OpEx savings, and 40% less energy use. For more information, please visit www.vvater.com

VVater Media Office
media@vvater.com

5W PR
Nicholas Koulermos
vvater@5wpr.com

SOURCE: VVater LLC

View the original press release on ACCESS Newswire